Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

RosDorBank reported for 9 months of 2023 by RAS

11/16/23 RDRB

Kamaz unmanned have traveled 560,000 kilometers

11/16/23 KMAZ

Yandex has developed an electric bike

11/16/23 YNDX

Ozon reported for 9 months of 2023

11/16/23 OZON

Ozon's turnover doubled in January-September

11/16/23 OZON

Etalon shareholders to discuss redomiciliation to Russia

11/16/23 ETLN

Cisco Systems announced a quarterly dividend

11/16/23 CSCO

Cisco reports 3 months of fiscal year 2024

11/16/23 CSCO

Moscow Exchange resumes trading in RN-Western Siberia shares

11/15/23 CHGZ

Transneft shareholders approve share split

11/15/23 TRNFP